| Welcome to Palatin's Investor Relations Information Site. We are pleased to provide you with information regarding Palatin Technologies' financial highlights. For your convenience, we provide a library of press releases, events and webcasts, as well as prefiltered links to the EDGAR database. |
|
|
| |
Palatin at-a-Glance: |
 |
 |
 |
| |
| Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing melanocortin-based and natriuretic peptide receptor therapeutics. The Company is developing bremelanotide for treatment of hemorrhagic shock, PL-3994 for treatment of acute systemic hypertension and acute chronic heart failure, and PL-6983 for treatment of male and female sexual dysfunction. |
|
|
|
 |
|
 |
|
|
|
|
|
|
|
| |
| (as of 3/31/08) |
|
| AMEX symbol: |
PTN |
| Shares outstanding: |
palatin |
| Common: |
85 million |
| Fully diluted: |
100 million |
| 52-wk price range: |
$0.19 - $2.09 |
| Market cap: |
$24 million |
| Employees: |
45 |
| Headquarters: |
Cranbury, NJ |
| Fiscal year end: |
June 30th |
| CEO: |
Dr. Carl Spana |
|
|
|
|
|
|
|
| |
|
|
Portions of this website may contain forward-looking statements concerning the future business, operating results and/or financial condition of Palatin Technologies, Inc. as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of uncertainties that could cause actual performance and results to differ materially from those anticipated by such forward-looking statements. For more information about these risks, please see the documents that the Company files from time to time with the Securities and Exchange Commission. Any forward-looking statements on this website are based on current expectations, and Palatin Technologies assumes no obligation to update them.
